Is it time to adopt proton pump inhibitors in the prevention of non-steroidal anti-inflammatory drug gastropathy?
Malki
S A
SA
University of Melbourne, Department of Medicine, Western Hospital, Australia.
Yeomans
N D
ND
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001562:Benzimidazoles / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D064747:Lansoprazole; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077402:Pantoprazole; D054328:Proton Pump Inhibitors; D013272:Stomach Diseases / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D013454:Sulfoxides / Q000627:therapeutic use
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D013454:Sulfoxides; D064747:Lansoprazole; D000077402:Pantoprazole; D009853:Omeprazole